Cargando…
Abstract 47: AMD3100 (Plerixafor) As A Single-Dose Stem Cell Mobilizing Agent In Vascularized Composite Tissue Allograft (VCA) Transplantation In A Canine DLA-Mismatch Model
Autores principales: | Swearingen, Bruce J., Graves, Scott S., Storb, Rainer, Mathes, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504352/ http://dx.doi.org/10.1097/01.GOX.0000558321.87208.c1 |
Ejemplares similares
-
Abstract 40: AMD3100 (Plerixafor) As A Single-Dose Stem Cell Mobilizing Agent In Vascularized Composite Tissue Allograft (VCA) Transplantation In A Canine Model
por: Swearingen, Bruce J., et al.
Publicado: (2018) -
Abstract 48: A Clinically Relevant Protocol for Vascularized Composite Allotransplantation Using A Single Dose of AMD3100 for Stem Cell Mobilization
por: Swearingen, Bruce J., et al.
Publicado: (2017) -
Abstract 51: Tolerance Induction Protocol For VCA Across Full Mismatch Barriers In MHC-Defined Miniature Swine
por: Andrews, Alec R., et al.
Publicado: (2020) -
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US
Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019) -
Abstract 68: Tolerance Induction of Vascularized Composite Allografts Across a Class I Barrier in Swine
por: Lellouch, Alexandre G., et al.
Publicado: (2019)